Pharmaceutical manufacturer Viagra and Epine have an unbreakable source of $ 20 billion a year - HailNewsUp.com: provides the latest news from India and the world

Breaking

Monday, July 29, 2019

Pharmaceutical manufacturer Viagra and Epine have an unbreakable source of $ 20 billion a year

Pfizer and Mylan announced that they are adding two of their businesses to create a world power in low-cost drug markets.

Pfizer said on Monday that it is downloading upzones to its portfolio of drugs, which are no longer preserved by patents like Viagra, Lipitor, and Celebrex. To make a new company, he is getting up a zone with his rival, Mylen, who makes epiphanies.
Under the terms of the agreement, Pfizer shareholders will gain more control over the company with 57% ownership and the shareholders of Mylan shareholders will be the rest.
The new company will have a new name, it will still be announced. The combined company is expected to generate annual revenue of $ 20 billion and it will be based in the United States. The Wall Street Journal said for the first time that the talks were happening in the weekend.
The management team will include people from Mylan and Upjohn. The current president of Mylan, Robert Corey will be its executive president and current president Michael Geetler will be the CEO. Hilbert Brest, the current Executive Director of Mylan, will retire once the agreement is closed.
Mylan (MYL) shares went up 15% in the first operation. Pfizer (PFE) shares fell nearly 3%
Both drugmakers have recently lost exclusive rights to manufacture medicines, which were big money producers for businesses. Viagra erectile dysfunction drug produced an estimated $ 1.4 billion in annual sales for Pfizer in 2017, before Teva Pharmaceuticals introduced a generalized version of the tablet in 2017, which quickly consumed market share.
Mylan's first generic contender for Epine, an emergency treatment for allergic reactions, was approved last year by the FDA. Two years after Mellon increased the price of the product by more than 400%, the appendix was added to the list of FP drug deficiency, which caused public resentment.
Over the last three years, Mylan's shares have lost 60% of their value. Jefferies analyst Jared Holz told CNN Business, "The exit of Brest" is clearly positive for health shareholders.
He blamed the management of Mylan for "significant exemption" in the valuation of the company's shares.
Other drugs in Pfizer's Epogen portfolio include XNAXx anxiety medications, Zoloft Depression medicine, and Lipitor, which treat high cholesterol. Upjohn recorded a decline of several million dollars in sales during the first quarter.
One of the world's largest pharmaceutical manufacturers, Pfizer works separately to expand its brand-name drug portfolio, and last month agreed to spend $ 11 billion to buy company Aerera Biopharma, which is a small company which is developing drugs for potentially attractive treatment remedies.
Pfizer is also launching a joint venture with GlaxoSmithKline (GLAXF), which will have an estimated $ 12.7 billion in annual sales. This agreement, which is expected to be closed in the second half of this year, will bring together Great Over-the-Counter products of Pfizer such as Centrum and Calvert, along with the main GSK brands, including Xfreen and Nicorette.